Skip to main content
Top
Published in: Current Rheumatology Reports 4/2010

Open Access 01-08-2010

Vitamin D and Systemic Lupus Erythematosus: Bones, Muscles, and Joints

Author: Nancy E. Lane

Published in: Current Rheumatology Reports | Issue 4/2010

Login to get access

Abstract

Vitamin D3, or cholecalciferol, is the naturally occurring form of vitamin D that is converted in the skin and hydroxylated in the liver and kidney to the active form found in humans. The main role for vitamin D is calcium homeostasis, and low levels of vitamin D result in lower gastrointestinal absorption of calcium. Vitamin D is also critical for mineralization of bone tissue, muscle function, and coordination. Recent studies have found prevention of bone mass loss and reduction in falls and fractures in patients supplemented with vitamin D. A high percentage of systemic lupus erythematosus patients are reported to have insufficient or deficient levels of vitamin D. This paper reviews the biology of vitamin D, its role in calcium homeostasis, and how it contributes to the maintenance of bone, muscle, and joint function in older adults and individuals with systemic lupus erythematosus.
Literature
1.
go back to reference Dusso AS, Brown AJ: Mechanism of vitamin D action and its regulation. Am J Kidney Dis 1998, 32(2 Suppl 2):S13–S24.CrossRefPubMed Dusso AS, Brown AJ: Mechanism of vitamin D action and its regulation. Am J Kidney Dis 1998, 32(2 Suppl 2):S13–S24.CrossRefPubMed
2.
go back to reference Malabanan AO, Holick MF: Vitamin D and bone health in postmenopausal women. J Womens Health (Larchmt) 2003, 12:151–156.CrossRef Malabanan AO, Holick MF: Vitamin D and bone health in postmenopausal women. J Womens Health (Larchmt) 2003, 12:151–156.CrossRef
3.
go back to reference Lips P: Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001, 22:477–501.CrossRefPubMed Lips P: Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001, 22:477–501.CrossRefPubMed
4.
go back to reference Heaney RP, Dowell MS, Hale CA, Bendich A: Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003, 22:142–146.PubMed Heaney RP, Dowell MS, Hale CA, Bendich A: Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003, 22:142–146.PubMed
5.
go back to reference Mingrone G, Greco AV, Castagneto M, Gasbarrini G: A woman who left her wheelchair. Lancet 1999, 353:806.CrossRefPubMed Mingrone G, Greco AV, Castagneto M, Gasbarrini G: A woman who left her wheelchair. Lancet 1999, 353:806.CrossRefPubMed
6.
go back to reference Prabhala A, Garg R, Dandona P: Severe myopathy associated with vitamin D deficiency in western New York. Arch Intern Med 2000, 24:160:1199–1203CrossRef Prabhala A, Garg R, Dandona P: Severe myopathy associated with vitamin D deficiency in western New York. Arch Intern Med 2000, 24:160:1199–1203CrossRef
7.
go back to reference Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al.: Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or = 60 y. Am J Clin Nutr 2004, 80:752–758.PubMed Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al.: Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or = 60 y. Am J Clin Nutr 2004, 80:752–758.PubMed
8.
go back to reference Bischoff HA , Borchers M, Gudat F, et al.: In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 2001, 33:19–24.CrossRefPubMed Bischoff HA , Borchers M, Gudat F, et al.: In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 2001, 33:19–24.CrossRefPubMed
9.
go back to reference •• Ceglia L: Vitamin D and skeletal muscle tissue and function. Mol Aspects Med 2008, 29:407–414. This is an outstanding review of the basic and translational science of the VDR in muscle tissue and muscle functionCrossRefPubMed •• Ceglia L: Vitamin D and skeletal muscle tissue and function. Mol Aspects Med 2008, 29:407–414. This is an outstanding review of the basic and translational science of the VDR in muscle tissue and muscle functionCrossRefPubMed
10.
go back to reference Drittanti L, deBoland AR, Boland R: Modulation of DNA synthesis in cultured muscle cells by 1,25dihydroxyvitamin D-3. Biochim Biophys Acta 1989, 1014:112–119.CrossRefPubMed Drittanti L, deBoland AR, Boland R: Modulation of DNA synthesis in cultured muscle cells by 1,25dihydroxyvitamin D-3. Biochim Biophys Acta 1989, 1014:112–119.CrossRefPubMed
11.
go back to reference Kalueff AV, Lou YR, Laaksi I, Tuohimaa P: Impaired motor performance in mice lacking neurosensory vitamin D receptors. Brain Res Bull 2004, 64:25–29.CrossRefPubMed Kalueff AV, Lou YR, Laaksi I, Tuohimaa P: Impaired motor performance in mice lacking neurosensory vitamin D receptors. Brain Res Bull 2004, 64:25–29.CrossRefPubMed
12.
go back to reference Hopkinson NS, Li KW, Kehoe A, et al.: Vitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease. Am J Clin Nutr 2008, 87:385–390.PubMed Hopkinson NS, Li KW, Kehoe A, et al.: Vitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease. Am J Clin Nutr 2008, 87:385–390.PubMed
13.
go back to reference Yoshikawa S, Nakamura T, Tanabe H, Imamura T: Osteomalacic myopathy. Endocrinol Jpn 1979, 26(Suppl):65–72PubMed Yoshikawa S, Nakamura T, Tanabe H, Imamura T: Osteomalacic myopathy. Endocrinol Jpn 1979, 26(Suppl):65–72PubMed
14.
go back to reference Sato Y, Iwamoto J, Kanoko T, Satoh K: Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke. A randomized controlled trial. Cerebrovasc Dis 2005, 20:187–192. Sato Y, Iwamoto J, Kanoko T, Satoh K: Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke. A randomized controlled trial. Cerebrovasc Dis 2005, 20:187–192.
15.
go back to reference Bischoff HA, Stähelin HB, Dick W, et al.: Effects of vitamin D and calcium supplementation on falls: a randomized controlled trials. J Bone Miner Res 2003, 18:343–351.CrossRefPubMed Bischoff HA, Stähelin HB, Dick W, et al.: Effects of vitamin D and calcium supplementation on falls: a randomized controlled trials. J Bone Miner Res 2003, 18:343–351.CrossRefPubMed
16.
go back to reference Bischoff-Ferrari H, Dietrich T, Orav EJ, Dawson-Hughes B: Positive association between 25-hydroxyvitamin D levels and bone mineral density; a population based study of younger and older adults. Am J Med 2004, 116:634–639.CrossRefPubMed Bischoff-Ferrari H, Dietrich T, Orav EJ, Dawson-Hughes B: Positive association between 25-hydroxyvitamin D levels and bone mineral density; a population based study of younger and older adults. Am J Med 2004, 116:634–639.CrossRefPubMed
17.
go back to reference Ooms ME, Roos JC, Bezemer PD, et al.: Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab 1995, 80:1052–1058.CrossRefPubMed Ooms ME, Roos JC, Bezemer PD, et al.: Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab 1995, 80:1052–1058.CrossRefPubMed
18.
go back to reference • Cauley JA, Lacroix AZ, Wu L, et al.: Serum 25 hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 2008, 149:242–250. This was an important study that determined in a large cohort of older women that low levels of serum 25(OH)D significantly increased the risk of hip fractures. Although these data do not determine whether the effect is through muscle or bone, the result is valid and supports the need to maintain 25(OH)D at levels at or above 32 ng/mLPubMed • Cauley JA, Lacroix AZ, Wu L, et al.: Serum 25 hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 2008, 149:242–250. This was an important study that determined in a large cohort of older women that low levels of serum 25(OH)D significantly increased the risk of hip fractures. Although these data do not determine whether the effect is through muscle or bone, the result is valid and supports the need to maintain 25(OH)D at levels at or above 32 ng/mLPubMed
19.
go back to reference Lips P, van Schoor NM, Bravenboer N: Vitamin D related disorders. In Primer of Metabolic Bone Diseases, edn 7. Edited by Rosen C. Washington, DC: American Society of Bone and Mineral Research; 2009:329–334 Lips P, van Schoor NM, Bravenboer N: Vitamin D related disorders. In Primer of Metabolic Bone Diseases, edn 7. Edited by Rosen C. Washington, DC: American Society of Bone and Mineral Research; 2009:329–334
20.
go back to reference Trivedi D, Doll R, Khaw KT: Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. BMJ 2003, 326:469.CrossRefPubMed Trivedi D, Doll R, Khaw KT: Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. BMJ 2003, 326:469.CrossRefPubMed
21.
go back to reference Chapuy MC, Arlot ME, Duboeuf F, et al.: Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992, 327:1627–1642.CrossRef Chapuy MC, Arlot ME, Duboeuf F, et al.: Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992, 327:1627–1642.CrossRef
22.
go back to reference Dawson-Hughes B: Calcium and vitamin D. In Primer of Metabolic Bone Diseases, edn 7. Edited by Rosen C. Washington, DC: American Society of Bone and Mineral Research; 2009:231–233 Dawson-Hughes B: Calcium and vitamin D. In Primer of Metabolic Bone Diseases, edn 7. Edited by Rosen C. Washington, DC: American Society of Bone and Mineral Research; 2009:231–233
23.
go back to reference Dawson-Hughes B, Heaney RP, Holick MK, et al.: Estimates of optimal vitamin D status. Osteoporos Int 2005, 16:713–716.CrossRefPubMed Dawson-Hughes B, Heaney RP, Holick MK, et al.: Estimates of optimal vitamin D status. Osteoporos Int 2005, 16:713–716.CrossRefPubMed
24.
go back to reference Armas LA, Hollis BW, Heaney RP: Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004, 89:5387–5391.CrossRefPubMed Armas LA, Hollis BW, Heaney RP: Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004, 89:5387–5391.CrossRefPubMed
25.
go back to reference Toloza SM, Cole DE, Gladman DD, et al.: Vitamin D insufficiency in a large female SLE cohort. Lupus 2010, 19:13–19.CrossRefPubMed Toloza SM, Cole DE, Gladman DD, et al.: Vitamin D insufficiency in a large female SLE cohort. Lupus 2010, 19:13–19.CrossRefPubMed
26.
go back to reference Borba VZ, Vieira JG, Kasamatsu T, et al.: Vitamin D deficiency in patients with active systemic lupus erythematous. Osteoporos Int 2009, 20:427–433.CrossRefPubMed Borba VZ, Vieira JG, Kasamatsu T, et al.: Vitamin D deficiency in patients with active systemic lupus erythematous. Osteoporos Int 2009, 20:427–433.CrossRefPubMed
Metadata
Title
Vitamin D and Systemic Lupus Erythematosus: Bones, Muscles, and Joints
Author
Nancy E. Lane
Publication date
01-08-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 4/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0106-1

Other articles of this Issue 4/2010

Current Rheumatology Reports 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.